Orilanolimab
As of the edition of 20 October 2026, Orilanolimab is an antibody: stopped in 2024; acts on FCGRT.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Antibody
- Registered trials
- 8, 7 stopped early
- Disease areas
- Immune system; Cancer; Nervous system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Orilanolimab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| FCGRT | IgG receptor FcRn large subunit p51 | P55899 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 5 | 0 | 0 | 5 |
| All trials | 8 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Syntimmune | Lead sponsor of trials | 2016 to now |
| AstraZeneca | Lead sponsor of trials | 2017 to now |